Eli Lilly Files 8-K on Financial Results & Debt Notes

TL;DR

**Eli Lilly just dropped an 8-K on financial results and debt, keep an eye on those long-term notes.**

AI Summary

Eli Lilly and Company filed an 8-K on February 6, 2024, to report its financial results and condition, specifically mentioning various debt notes with maturity dates ranging from June 1, 2025, to 2061. This filing is crucial for investors as it provides transparency into the company's financial health and its ability to manage long-term debt obligations, which can impact future profitability and stock valuation.

Why It Matters

This filing provides a snapshot of Eli Lilly's financial health, particularly its debt structure, which is vital for investors to assess the company's stability and future growth potential.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial results and existing debt instruments, not indicating any immediate new risks or significant changes.

Analyst Insight

Investors should review Eli Lilly's full financial statements to understand the specific amounts and terms of these debt obligations and how they fit into the company's overall financial strategy.

Key Numbers

• June 1, 2025 — Maturity Date (for A718 Notes)
• June 2, 2026 — Maturity Date (for A1.625 Notes)
• June 3, 2030 — Maturity Date (for A2.125 Notes)
• 2031 — Maturity Date (for A625 Notes)
• 2033 — Maturity Date (for A500 Notes)
• January 1, 2036 — Maturity Date (for A6.77 Notes)
• 2043 — Maturity Date (for A1625 Notes)
• 2049 — Maturity Date (for A1.700 Notes)

Key Players & Entities

• ELI LILLY AND COMPANY (company) — the registrant filing the 8-K
• Indiana (location) — state of incorporation
• 001-06351 (identifier) — Commission File Number
• 35-0470950 (identifier) — I.R.S. Employer Identification No.
• Lilly Corporate Center (location) — Address of Principal Executive Offices
• Indianapolis (location) — City of Principal Executive Offices
• 46285 (location) — Zip Code of Principal Executive Offices
• 317-276-2000 (phone_number) — Registrant’s Telephone Number
• February 6, 2024 (date) — Date of Earliest Event Reported

Forward-Looking Statements

• Eli Lilly will successfully manage its debt obligations maturing in 2025. (ELI LILLY AND COMPANY) — high confidence, target: 2025-12-31
• The company's long-term debt structure will remain stable through 2030. (ELI LILLY AND COMPANY) — medium confidence, target: 2030-12-31

FAQ

Filing Documents

• lly-20240206.htm (8-K) — 49KB
• q423lillysalesandearningsp.htm (EX-99.1) — 251KB
• logoa31a.jpg (GRAPHIC) — 14KB
• 0000059478-24-000032.txt ( ) — 564KB
• lly-20240206.xsd (EX-101.SCH) — 5KB
• lly-20240206_def.xml (EX-101.DEF) — 19KB
• lly-20240206_lab.xml (EX-101.LAB) — 41KB
• lly-20240206_pre.xml (EX-101.PRE) — 20KB
• lly-20240206_htm.xml (XML) — 10KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing. Attached hereto as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 6, 2024, announcing the financial results of Eli Lilly and Company for the quarter and year ended December 31, 2023.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release of Eli Lilly and Company, dated February 6, 2024 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ELI LILLY AND COMPANY (Registrant) By: /s/ Donald A. Zakrowski Name: Donald A. Zakrowski Title: Senior Vice President, Finance, and Chief Accounting Officer Date: February 6, 2024

View Full Filing

View this 8-K filing on SEC EDGAR